Sangamo Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
March 13, 2024 at 07:55 am
Share
Sangamo Therapeutics, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported sales was USD 2.04 million compared to USD 27.23 million a year ago. Net loss was USD 60.3 million compared to USD 51.97 million a year ago. Basic loss per share from continuing operations was USD 0.34 compared to USD 0.32 a year ago.
For the full year, the company reported sales was USD 176.23 million compared to USD 111.3 million a year ago. Net loss was USD 257.83 million compared to USD 192.28 million a year ago. Basic loss per share from continuing operations was USD 1.48 compared to USD 1.25 a year ago. Diluted loss per share from continuing operations was USD 1.48 compared to USD 1.25 a year ago.
Sangamo Therapeutics, Inc. is a genomic medicines company that is developing medicines for neurological diseases. The Company's neurology preclinical development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases, and development of novel engineered adeno-associated virus (AAV) capsids to deliver its therapies to the intended neurological targets. The Company's zinc finger epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid discovery platform is expanding delivery beyond intrathecal delivery capsids, including in the central nervous system. Its clinical-stage product candidates are Isaralgagene civaparvovec, also known as ST-920, its wholly-owned gene therapy product candidate for the treatment of Fabry disease, and TX200, its wholly-owned CAR-Treg cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation.